FrancophonIA/ELRC3.0 huggingface dataset:
English: The overall safety profile of capecitabine is based on data from over 3000 patients treated with capecitabine as monotherapy or capecitabine in combination with different chemotherapy regimens in multiple indications.
Croatian: Ukupni sigurnosni profil kapecitabina temelji se na podacima od preko 3000 bolesnika koji su liječeni kapecitabinom kao monoterapijom ili kapecitabinom kao dijelom različitih kemoterapijskih protokola, u različitim indikacijama.
English: According to immunohistochemical studies, thymidine phosphorylase appears to be in large part localised in tumour stromal cells.
Croatian: Prema imunohistokemijskim ispitivanjima, izgleda da je timidin fosforilaza većinom lokalizirana u tumorskim stromalnim stanicama.
English: The sequential enzymatic biotransformation of capecitabine to 5-FU leads to higher concentrations within tumour tissues.
Croatian: Enzimska biotransformacija kapecitabina u 5-FU dovodi do veće koncentracije u tumorskim tkivima.
English: NCIC CTC grade 2 diarrhoea is defined as an increase of 4 to 6 stools/day or nocturnal stools, grade 3 diarrhoea as an increase of 7 to 9 stools/day or incontinence and malabsorption.
Croatian: Proljev 2. stupnja (prema NCIC CTC) definira se kao povećanje broja stolica na 4 do 6 stolica dnevno ili pojava noćnih stolica, proljev 3. stupnja definira se kao povećanje broja stolica na 7 do 9 stolica dnevno ili inkontinencija i malapsorpcija.
English: Some of these side effects are more common when capecitabine is used with other medicines for the treatment of cancer.
Croatian: Neke od ovih nuspojava javljaju se češće kada se kapecitabin primjenjuje zajedno s drugim lijekovima za liječenje raka.
English: Cardiotoxicity has been associated with fluoropyrimidine therapy, including myocardial infarction, angina, dysrhythmias, cardiogenic shock, sudden death and electrocardiographic changes (including very rare cases of QT prolongation).
Croatian: Kardiotoksičnost se povezuje s fluoropirimidinskom terapijom i uključuje infarkt miokarda, anginu, disritmije, kardiogeni šok, iznenadnu smrt i elektrokardiografske promjene (uključujući vrlo rijetke slučajeve produljenja QT-intervala).
English: As the potential for harm to the nursing infant is unknown, breast-feeding should be discontinued while receiving treatment with capecitabine and for 2 weeks after the final dose.
Croatian: Budući da mogući štetni učinci na dojenče nisu poznati, dojenje treba prekinuti tijekom liječenja kapecitabinom i još 2 tjedna nakon posljednje doze.
English: Cardiotoxicity (see section 4.4):
Croatian: Kardiotoksičnost (vidjeti dio 4.4)
English: 10.4 months
Croatian: 10,4 mjeseca
English: - in combination with docetaxel (see section 5.1) for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy.
Croatian: - u kombinaciji s docetakselom (vidjeti dio 5.1) za liječenje bolesnika s lokalno uznapredovalim ili metastatskim karcinomom dojke nakon neuspjeha citotoksične kemoterapije.
English: Montagnani et al used the results from the above three studies to provide an overall analysis of randomised studies comparing FOLFIRI and XELIRI treatment regimens in the treatment of mCRC.
Croatian: Montagnani i sur. iskoristili su rezultate triju gore navedenih ispitivanja kako bi proveli sveukupnu analizu randomiziranih ispitivanja u kojima se uspoređivala primjena protokola liječenja FOLFIRI i XELIRI u liječenju metastatskog kolorektalnog karcinoma.
English: In a clinical pharmacokinetic interaction study, after a single 20 mg dose of warfarin, capecitabine treatment increased the AUC of S-warfarin by 57% with a 91% increase in INR value.
Croatian: U jednom kliničkom ispitivanju farmakokinetičkih interakcija, nakon jednokratne doze varfarina od 20 mg, uzimanje kapecitabina povećalo je AUC S-varfarina za 57% te vrijednosti INR za 91%.
English: At the beginning of a treatment cycle, if a treatment delay is indicated for either capecitabine or the other medicinal product(s), then administration of all therapy should be delayed until the requirements for restarting all medicinal products are met.
Croatian: Ako je na početku liječenja indicirana odgoda liječenja bilo kapecitabinom, bilo drugim lijekom (lijekovima), primjena cjelokupne terapije mora se odgoditi dok ne budu zadovoljeni uvjeti za početak liječenja svim lijekovima.
English: - History of severe and unexpected reactions to fluoropyrimidine therapy, - Hypersensitivity to capecitabine or to any of the excipients listed in section 6.1 or fluorouracil, - In patients with known complete absence of dihydropyrimidine dehydrogenase (DPD) activity
Croatian: - Prethodne teške i neočekivane nuspojave na fluoropirimidinsku terapiju, - Preosjetljivost na kapecitabin ili neku od pomoćnih tvari navedenih u dijelu 6.1 ili na fluorouracil, - Bolesnici s poznatim potpunim nedostatkom aktivnosti dihidropirimidin dehidrogenaze (DPD)
English: Dehydration.
Croatian: Dehidracija
English: Ecansya contains capecitabine, which itself is not a cytostatic medicine.
Croatian: Ecansya sadrži kapecitabin, koji sam po sebi nije citostatik.
English: In addition to the ADRs described in tables 4 and 5, and based on the above pooled analysis from clinical safety data from 7 clinical trials, encephalopathy was also associated with the use of capecitabine monotherapy with an incidence of less than 0.1%.
Croatian: Uz nuspojave opisane u Tablicama 4 i 5 te temeljeno na gore navedenoj analizi združenih podataka o kliničkoj sigurnosti primjene iz 7 kliničkih ispitivanja, encefalopatija je također bila povezana s uzimanjem kapecitabina kao monoterapije, s incidencijom manjom od 0,1%.
English: The 5 year OS rate was 78% for XELOX versus 74% for 5-FU/LV.
Croatian: Petogodišnja stopa ukupnog preživljenja bila je 78% za XELOX nasuprot 74% za 5-FU/LV.
English: Cardiovascular toxicity (e.g. PR- and QT-interval prolongation) was detectable in cynomolgus monkeys after intravenous administration (100 mg/kg) but not after repeated oral dosing (1379 mg/m2/day).
Croatian: Kardiovaskularna toksičnost (npr. produljenje PR i QT intervala) utvrđena je u cinomolgus majmuna nakon intravenske primjene (100 mg/kg), ali ne i nakon ponovljene oralne doze (1379 mg/m2 na dan).
English: Thymidine phosphorylase activity was measured and found to be 4 times greater in primary colorectal tumour than in adjacent normal tissue.
Croatian: Izmjerena je aktivnost timidin fosforilaze i nađeno je da je ona 4 puta veća u primarnom kolorektalnom karcinomu nego u okolnom zdravom tkivu.
English: Dose per administration (mg)
Croatian: Doza po jednoj primjeni (mg)
English: Sleep disorder, Anxiety
Croatian: Psihijatrijski poremećaji poremećaji spavanja, anksioznost
English: Severe skin reactions: Ecansya can induce severe skin reactions such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis.
Croatian: Ecansya može potaknuti razvoj teških kožnih reakcija poput Stevens-Johnsonova sindroma i toksične epidermalne nekrolize.
English: Table 5 lists ADRs associated with the use of capecitabine in combination with different chemotherapy regimens in multiple indications based on safety data from over 3000 patients.
Croatian: Tablici 5 nalazi se popis nuspojava povezanih s primjenom kapecitabina u različitim kemoterapijskim protokolima, u različitim indikacijama, koji se temelji na sigurnosnim podacima dobivenim od više od 3000 bolesnika.
English: The median follow up at the time of the primary analyses in the intent-to-treat population was 2.1 years; data from analyses following an additional 6 months of follow up are also included in table 9.
Croatian: Medijan praćenja u vrijeme primarnih analiza u populaciji bolesnika predviđenih za liječenje bio je 2,1 godinu; podaci iz analiza nakon dodatnih 6 mjeseci praćenja također su sadržani u Tablici 9.
English: Further catalytic activation of 5'-DFUR then occurs by thymidine phosphorylase (ThyPase).
Croatian: Daljnja katalitička aktivacija 5'-DFUR odvija se pomoću timidin fosforilaze (ThyPase).
English: - Steven-Johnson syndrome: if you experience painful red or purplish rash that spreads and blisters and/or other lesions begin to appear in the mucous membrane (e.g. mouth and lips), in particular if you had before light sensitivity, infections of the respiratory system (e.g. bronchitis) and/or fever.
Croatian: - Stevens-Johnsonov sindrom: ako dobijete bolan crveni ili ljubičasto-crveni osip koji se širi i počnu se javljati mjehurići i/ili druga oštećenja na sluznici (npr. u ustima i na usnicama), osobito ako ste ranije bili osjetljivi na svjetlost ili imali infekcije dišnog sustava (npr. bronhitis) i/ili vrućicu.
English: In an interaction study with single-dose warfarin administration, there was a significant increase in the mean AUC (+57%) of S-warfarin.
Croatian: Tijekom ispitivanja interakcije s jednokratnom dozom varfarina uočeno je znatno povećanje površine ispod krivulje (AUC) (+57%) S-varfarina.
English: In addition to the ADRs described in tables 4 and 5, the following ADRs with an incidence of less than 0.1% were associated with the use of capecitabine monotherapy based on a pooled analysis from clinical safety data from 7 clinical trials including 949 patients (2 phase III and 5 phase II clinical trials in metastatic colorectal cancer and metastatic breast cancer): cardiomyopathy, cardiac failure, sudden death, and ventricular extrasystoles.
Croatian: Uz nuspojave opisane u Tablicama 4 i 5, sljedeće nuspojave s incidencijom manjom od 0,1% su bile povezane s uporabom kapecitabina kao monoterapije, temeljeno na analizi združenih podataka o kliničkoj sigurnosti primjene iz 7 kliničkih ispitivanja na 949 bolesnika (2 faze III i 5 faza II kliničkih ispitivanja u bolesnika s metastatskim kolorektalnim karcinomom i metastatskim karcinomom dojke): kardiomiopatija, zatajenje srca, iznenadna smrt i ventrikularne ekstrasistole.
English: Based on the population pharmacokinetic analysis, which included patients with a wide range of ages (27 to 86 years) and included 234 (46%) patients greater or equal to 65, age has no influence on the pharmacokinetics of 5'-DFUR and 5-FU.
Croatian: Starije osobe: Na temelju rezultata populacijske farmakokinetičke analize, koja je uključivala bolesnike širokoga dobnog raspona (od 27 do 86 godina) te 234 (46%) bolesnika od 65 godina ili starijih, ustanovljeno je da dob nema utjecaja na farmakokinetiku 5'-DFUR i 5-FU.
English: These dose adjustment recommendations for renal impairment apply both to monotherapy and combination use (see also section "Elderly" below).
Croatian: Preporuke o prilagodbi doziranja u slučaju oštećenja bubrežne funkcije odnose se i na monoterapiju i na kombiniranu primjenu (vidjeti također dio ispod „Starije osobe“).
English: In repeat-dose toxicity studies, daily oral administration of capecitabine to cynomolgus monkeys and mice produced toxic effects on the gastrointestinal, lymphoid and haemopoietic systems, typical for fluoropyrimidines.
Croatian: U ispitivanju toksičnosti ponovljene doze, oralna dnevna primjena kapecitabina izazvala je u cinomolgus majmuna i miševa toksične učinke na gastrointestinalnom, limfnom i hematopoteskom sustavu, što je tipično za fluoropirimidine.
English: Ecansya is used in the treatment of colon, rectal, gastric, or breast cancers.
Croatian: Ecansya se koristi za liječenje karcinoma kolona, rektuma, želuca ili dojke.
English: Median overall survival time was 703 days (95% CI: 671; 745) in patients treated with capecitabine-containing regimens and 683 days (95% CI: 646; 715) in patients treated with 5-FU-containing regimens.
Croatian: Medijan ukupnog vremena preživljenja iznosio je 703 dana (95% CI: 671; 745) u bolesnika liječenih protokolima koji su sadržavali kapecitabin i 683 dana (95% CI: 646; 715) u bolesnika liječenih protokolima koji su sadržavali 5-FU.
English: Aluminium/aluminium or PVC/PVdC/aluminium blister containing 10 film-coated tablets.
Croatian: Aluminij/aluminij ili PVC/PVdC/aluminij blisteri sadrže 10 filmom obloženih tableta.
English: There is some evidence that dexpanthenol is effective for hand-foot syndrome prophylaxis in patients treated with Ecansya.
Croatian: Postoje dokazi o tome da je dekspantenol djelotvoran za profilaksu sindroma šaka-stopalo u bolesnika liječenih lijekom Ecansya.
English: Capecitabine is first metabolised by hepatic carboxylesterase to 5'-DFCR, which is then converted to 5-DFUR by cytidine deaminase, principally located in the liver and tumour tissues.
Croatian: Kapecitabin se najprije metabolizira jetrenom karboksilesterazom u 5'-DFCR, koji se pomoću citidin deaminaze pretvara u 5'-DFUR koji se uglavnom nalazi u jetri i tumorskim tkivima.
English: Capecitabine may cause dizziness, fatigue and nausea.
Croatian: Kapecitabin može uzrokovati omaglicu, umor i mučninu.
English: 5-Fluorouracil 400 mg/m intravenous bolus, followed by 600 mg/ 2 intravenous 22 hr
Croatian: 5-fluorouracil intravenski bolus 400 mg/m2, nakon kojeg slijedi 600 mg/ m intravenski 22 sata placebo ili bevacizumab
English: Some of the ADRs are reactions commonly seen with the combination medicinal product (e.g. peripheral sensory neuropathy with docetaxel or oxaliplatin, hypertension seen with bevacizumab); however an exacerbation by capecitabine therapy cannot be excluded.
Croatian: Neke od nuspojava su reakcije koje se često viđaju pri primjeni kombinacijskog lijeka (npr. periferna senzorna neuropatija kod docetaksela ili oksaliplatina, povišeni krvni tlak kod bevacizumaba); ipak pogoršanje istih zbog uzimanja kapecitabina se ne može isključiti.
English: The pooled analysis includes 3097 patients treated with capecitabine-containing regimens and 3074 patients treated with 5-FU-containing regimens.
Croatian: Analiza združenih podataka obuhvatila je 3097 bolesnika liječenih protokolima koji su sadržavali kapecitabin i 3074 bolesnika liječenih protokolima koji su sadržavali 5-FU.
English: If you stop taking Ecansya
Croatian: Ako prestanete uzimati lijek Ecansya
English: Advanced gastric cancer:
Croatian: Uznapredovali karcinom želuca:
English: Caution must be exercised in patients with central or peripheral nervous system disease, e.g. brain metastasis or neuropathy (see section 4.8).
Croatian: Pozornost treba obratiti na bolesnike s bolešću središnjeg ili perifernog živčanog sustava, primjerice s metastazama u mozgu ili neuropatijom (vidjeti dio 4.8).
English: XELOX or XELOX+ Bevacizumab
Croatian: XELOX ili XELOX i bevacizumab oksaliplatin
English: Name and address of the manufacturers responsible for batch release Accord Healthcare Ltd.
Croatian: Naziv i adresa proizvođača odgovornog(ih) za puštanje serije lijeka u promet Accord Healthcare
English: +Fever,
Croatian: +infekcija,
English: If you have an unrecognised DPD deficiency and take Ecansya, you are at an increased risk of acute early-onset of severe forms of the side effects listed under section 4 Possible side effects.
Croatian: Ako ne znate da imate nedostatak DPD-a, a uzimate lijek Ecansya, imate povećan rizik od akutnog ranog nastupa teških oblika nuspojava navedenih u dijelu 4. Moguće nuspojave.
English: Based on genetic toxicity findings, male patients with female partners of reproductive potential should use effective contraception during treatment and for 3 months following the last dose of capecitabine.
Croatian: S obzirom na genotoksične učinke lijeka, muški bolesnici koji imaju partnerice reproduktivne dobi moraju koristiti učinkovitu metodu kontracepcije tijekom liječenja i još 3 mjeseca nakon posljednje doze kapecitabina.
English: If you forget to take Ecansya
Croatian: Ako ste zaboravili uzeti lijek Ecansya
English: (neuropathy) - if you have calcium imbalances (seen in blood tests) - if you have diabetes - if you cannot keep food or water in your body because of severe nausea and vomiting - if you have diarrhoea - if you are or become dehydrated - if you have imbalances of ions in your blood (electrolyte imbalances, seen in tests) - if you have a history of eye problems as you may need extra monitoring of your eyes - if you have a severe skin reaction.
Croatian: (neuropatiju) - ako imate poremećaj razine kalcija (vidi se iz nalaza krvnih pretraga) - ako imate šećernu bolest - ako ne možete zadržati hranu ili vodu u vašem tijelu uslijed jake mučnine ili povraćanja - ako imate proljev - ako ste dehidrirali - ako imate poremećaj razine iona u krvi (poremećaj ravnoteže elektrolita, vidi se iz nalaza pretraga) - ako ste ranije imali očnih tegoba jer će vam možda biti potrebna dodatna kontrola očiju - ako imate tešku kožnu reakciju.
English: All grades
Croatian: Svi stupnjevi
English: Other side effects are:
Croatian: Ostale nuspojave su:
English: A two-year mouse carcinogenicity study produced no evidence of carcinogenicity by capecitabine.
Croatian: Dvogodišnjim ispitivanjem kancerogenosti na miševima nije dokazana kancerogenost kapecitabina.
English: Women of childbearing potential/Contraception in males and females Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with capecitabine.
Croatian: Žene reproduktivne dobi/Kontracepcija u muškaraca i žena Žene reproduktivne dobi potrebno je savjetovati da tijekom liječenja kapecitabinom izbjegavaju trudnoću.
English: In patients with mild renal impairment (creatinine clearance 51-80 ml/min at baseline) no adjustment of the starting dose is recommended.
Croatian: U bolesnika s blagim oštećenjem bubrežne funkcije (početnim klirensom kreatinina 51-80 ml/min) nije potrebna prilagodba početne doze.
English: If grade 2 or 3 hand-foot syndrome occurs, administration of capecitabine should be interrupted until the event resolves or decreases in intensity to grade 1.
Croatian: Ako se razvije sindrom šaka-stopalo 2. ili 3. stupnja liječenje kapecitabinom mora se prekinuti do povlačenja tegoba ili smanjenja njihovog intenziteta na 1. stupanj.
English: Acute renal failure secondary to dehydration might be potentially fatal.
Croatian: Akutno zatajenje bubrega kao posljedica dehidracije može biti smrtonosno.
English: You must inform your doctor if you know that you have an allergy or over-reaction to this medicine, - if you previously have had severe reactions to fluoropyrimidine therapy (a group of anticancer medicines, such as fluorouracil), - if you are pregnant or breast-feeding, - if you have severely low levels of white cells or platelets in the blood (leucopenia, neutropenia or thrombocytopenia), - if you have severe liver or kidney problems, - if you know that you do not have any activity of the enzyme dihydropyrimidine dehydrogenase (DPD) - if you are being treated now or have been treated in the last 4 weeks with brivudine as part of herpes zoster (chickenpox or shingles) therapy.
Croatian: Morate obavijestiti svog liječnika ako znate da ste alergični ili preosjetljivi na ovaj lijek, - ako ste prethodno imali tešku reakciju na liječenje fluoropirimidinima (skupina lijekova protiv raka poput fluorouracila), - ako ste trudni ili ako dojite, - ako imate jako niske razine bijelih krvnih stanica ili krvnih pločica (leukopeniju, neutropeniju ili trombocitopeniju), - ako imate tešku bolest jetre ili bubrega, - ako znate da nemate nikakvu aktivnost enzima dihidropirimidin dehidrogenaze (DPD), - ako se liječite ili ste se u zadnja 4 tjedna liječili brivudinomu sklopu liječenja herpes zostera
English: The study contained two parts: an initial 2-arm part in which 634 patients were randomised to two different treatment groups, including XELOX or FOLFOX-4, and a subsequent 2x2 factorial part in which 1401 patients were randomised to four different treatment groups, including XELOX plus placebo, FOLFOX-4 plus placebo, XELOX plus bevacizumab, and FOLFOX-4 plus bevacizumab.
Croatian: Ispitivanje se sastojalo od dva dijela: prvog (inicijalnog) dijela u kojem je 634 bolesnika bilo randomizirano u dvije terapijske skupine: jedna skupina primala je XELOX protokol, a druga FOLFOX-4 protokol, i naknadnog 2x2 faktorijalnog dijela u kojem je 1401 bolesnik randomiziran u jednu od četiri različite terapijske skupine: XELOX i placebo, FOLFOX-4 i placebo, XELOX i bevacizumab te FOLFOX-4 i bevacizumab.
English: Number of 150 mg tablets, 300 mg tablets and/or 500 mg tablets per administration (each administration to be given morning and evening)
Croatian: Broj tableta od 150 mg, 300 mg i/ili 500 mg po jednoj primjeni (svaka doza uzima se ujutro i navečer)
English: Concomitant use of allopurinol with capecitabine should be avoided.
Croatian: Treba izbjegavati istodobnu primjenu alopurinola i kapecitabina.
English: These adverse reactions may be more common in patients with a prior history of coronary artery disease.
Croatian: Nuspojave mogu biti češće u bolesnika s anamnezom koronarne bolesti.
English: Caution must be exercised in patients with pre-existing hypo- or hypercalcaemia (see section 4.8).
Croatian: Pozornost treba obratiti na bolesnike s već postojećom hipokalcijemijom ili hiperkalcijemijom (vidjeti dio 4.8).
English: • Periodic safety update reports (PSURs)
Croatian: • Periodička izvješća o neškodljivosti lijeka (PSUR-evi)
English: Dose reduction should be applied as necessary (see section 4.2).
Croatian: Doza se smanjuje prema potrebi (vidjeti dio 4.2).
English: If unscheduled laboratory assessments during a treatment cycle show that the neutrophil count drops below 1.0 x 10
Croatian: Ako neplanirane laboratorijske pretrage tijekom ciklusa liječenja pokažu pad broja neutrofila ispod 1,0 x 10 9/l ili pad broja trombocita ispod 75 x 10
English: Colon and colorectal cancer:
Croatian: Karcinom kolona i kolorektalni karcinom:
English: In the event of accidental administration of brivudine to patients being treated with capecitabine, effective measures should be taken to reduce the toxicity of capecitabine.
Croatian: Ako se brivudin slučajno primijeni u bolesnika koji se liječe kapecitabinom, potrebno je poduzeti učinkovite mjere za smanjenje toksičnosti kapecitabina.
English: A population pharmacokinetic analysis was carried out after capecitabine treatment of 505 patients with colorectal cancer dosed at 1250 mg/m2 twice daily.
Croatian: Populacijska farmakokinetička analiza provedena je u skupini od 505 bolesnika s kolorektalnim karcinomom nakon liječenja kapecitabinom u dozi od 1250 mg/m2 dvaput dnevno.
English: An analysis of safety data in patients ≥ 60 years of age treated with capecitabine monotherapy and an analysis of patients treated with capecitabine plus docetaxel combination therapy showed an increase in the incidence of treatment-related grade 3 and 4 adverse reactions and treatment-related serious adverse reactions compared to patients < 60 years of age.
Croatian: Analiza podataka o sigurnosti primjene u bolesnika u dobi od 60 i više godina liječenih monoterapijom kapecitabinom i analiza bolesnika liječenih kombinacijom kapecitabina i docetaksela, pokazala je povećanje incidencije nuspojava 3. i 4. stupnja povezanih s liječenjem i ozbiljnih nuspojava povezanih s liječenjem, u usporedbi s bolesnicima mlađim od 60 godina.
English: Your doctor may want you to take a combination of 150 mg, 300 mg and 500 mg tablets for each dose.
Croatian: Liječnik će možda zahtijevati da za svaku dozu uzimate kombinaciju tableta od 150 mg, 300 mg i 500 mg.
English: A reduction of the starting dose in these patients may be considered to avoid serious toxicity.
Croatian: U tih se bolesnika radi izbjegavanja ozbiljne toksičnosti može razmotriti smanjenje početne doze.
English: Patients with certain heterozygous DPYD variants (including DPYD*2A, c.1679T>G, c.2846A>T and c.1236G>A/HapB3 variants) have been shown to have increased risk of severe toxicity when treated with capecitabine.
Croatian: Pokazalo se da bolesnici s određenim heterozigotnim varijantama gena DPYD (uključujući varijante DPYD*2A, c.1679T>G, c.2846A>T i c.1236G>A/HapB3) imaju povećan rizik od teške toksičnosti kada se liječe kapecitabinom.
English: The frequency of the heterozygous DPYD*2A genotype in the DPYD gene in Caucasian patients is around 1%, 1.1% for c.2846A>T, 2.6-6.3% for c.1236G>A/HapB3 variants and 0.07 to 0.1% for c.1679T>G.
Croatian: Učestalost heterozigotnog genotipa DPYD*2A u genu DYPD kod bolesnika bijele rase iznosi približno 1%, učestalost varijante c.2846A>T 1,1%, varijante c.1236G>A/HapB3 2,6-6,3%, a varijante c.1679T>G 0,07 do 0,1%.